NKTR vs AAPG
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
NKTR · Nektar Therapeutics$30.20 ▼ 7.19%
AAPG · Ascentage Pharma$11.97 ▼ 3.78%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- NKTR -48.5%
- AAPG -62.6%
Head to head
| Metric | NKTR | AAPG |
|---|---|---|
| Price | $30.20 | $11.97 |
| Change today | ▼ 7.19% | ▼ 3.78% |
| Market cap | $1.03B | $1.12B |
| Return, 3 months | -59.0% | -28.4% |
| Return, year to date | -28.6% | -54.4% |
| Return, 1 year | -44.4% | -60.9% |
| P/E (TTM) | – | – |
| P/B | 1.2 | 13.4 |
| P/E percentile vs own 5y | 20th | 98th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -20.4% | -41.5% |
| Net profit growth (YoY) | -56.7% | -206.4% |
| Gross margin | – | 93.9% |
| Operating margin | -303.6% | -216.7% |
| Net margin | -339.7% | -228.5% |
| Return on equity | -37.9% | -240.3% |
| Analyst target vs. price | +356.1% | +250.9% |
| Analyst buy share | 70% | 100% |
| RSI (14) | 23 | 29 |
| 30-day volatility | 53.9% | 64.7% |
| Max drawdown, 1 year | -69.9% | -65.1% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AAPG is the largest of the group by market value.
- NKTR has returned the most over the past year.
- NKTR is growing revenue fastest.
- AAPG keeps the most profit per dollar of sales.
- NKTR has been the calmest stock over the last 30 days.